198 related articles for article (PubMed ID: 21728742)
21. Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.
Takada Y; Sethi G; Sung B; Aggarwal BB
Mol Pharmacol; 2008 May; 73(5):1549-57. PubMed ID: 18287248
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
23. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
24. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
25. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Ge Y; Byun JS; De Luca P; Gueron G; Yabe IM; Sadiq-Ali SG; Figg WD; Quintero J; Haggerty CM; Li QQ; De Siervi A; Gardner K
Mol Pharmacol; 2008 Sep; 74(3):872-83. PubMed ID: 18556456
[TBL] [Abstract][Full Text] [Related]
27. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Dasmahapatra G; Almenara JA; Grant S
Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
[TBL] [Abstract][Full Text] [Related]
28. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
[TBL] [Abstract][Full Text] [Related]
29. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.
Pepper C; Thomas A; Hoy T; Tighe J; Culligan D; Fegan C; Bentley P
Cell Cycle; 2003; 2(1):53-8. PubMed ID: 12695689
[TBL] [Abstract][Full Text] [Related]
30. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
[No Abstract] [Full Text] [Related]
31. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR
Haematologica; 2010 Jul; 95(7):1098-105. PubMed ID: 20460644
[TBL] [Abstract][Full Text] [Related]
33. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Yu C; Krystal G; Dent P; Grant S
Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE; Garrett-Mayer E; Estey EH; Rudek MA; Smith BD; Greer JM; Drye DM; Mackey K; Dorcy KS; Gore SD; Levis MJ; McDevitt MA; Carraway HE; Pratz KW; Gladstone DE; Showel MM; Othus M; Doyle LA; Wright JJ; Pagel JM
Haematologica; 2012 Nov; 97(11):1736-42. PubMed ID: 22733022
[TBL] [Abstract][Full Text] [Related]
35. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol.
Li Y; Chinni SR; Senderowicz AM; Sarkar FH
Int J Oncol; 2000 Oct; 17(4):755-9. PubMed ID: 10995888
[TBL] [Abstract][Full Text] [Related]
36. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
Alonso M; Tamasdan C; Miller DC; Newcomb EW
Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.
Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S
Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404
[TBL] [Abstract][Full Text] [Related]
38. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.
Arguello F; Alexander M; Sterry JA; Tudor G; Smith EM; Kalavar NT; Greene JF; Koss W; Morgan CD; Stinson SF; Siford TJ; Alvord WG; Klabansky RL; Sausville EA
Blood; 1998 Apr; 91(7):2482-90. PubMed ID: 9516149
[TBL] [Abstract][Full Text] [Related]
39. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Pepper C; Thomas A; Hoy T; Fegan C; Bentley P
Br J Haematol; 2001 Jul; 114(1):70-7. PubMed ID: 11472347
[TBL] [Abstract][Full Text] [Related]
40. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.
Dispenzieri A; Gertz MA; Lacy MQ; Geyer SM; Fitch TR; Fenton RG; Fonseca R; Isham CR; Ziesmer SC; Erlichman C; Bible KC
Haematologica; 2006 Mar; 91(3):390-3. PubMed ID: 16503551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
